0
Skip to Content
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Nordic Migraine Symposium 2026
Home
Agenda
Venue & Accommodation
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW
Home
Agenda
Venue & Accommodation
Folder: Previous years
Back
NMS 2025
NMS 2024
NMS 2023
NMS 2022
NMS 2021
NMS 2020
NMS 2019
Contact
REGISTER NOW

When to switch? Anti-CGRPs and gepants

Session 1: New treatments – Evaluation and management

Bianca Raffaelli

Neurology consultant, Department of Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany

Download presentation

Previous

When to evaluate effectiveness?- Anti-CGRPs and gepants

Next

Does vestibular migraine exist? Pro

You Might Also Like

Related Embedded Video Item Thumbnail Swedish digi-physical headache center
Related Embedded Video Item Thumbnail Artificial intelligence in migraine management
Related Embedded Video Item Thumbnail for treating in the prodromal phase?
Related Embedded Video Item Thumbnail PACAP in migraine and cluster headache
Related Embedded Video Item Thumbnail for using triptan during the aura phase?

Privacy policy

Teva Privacy Notice |Teva Pharmaceuticals

Legal Notes | Teva Pharmaceuticals

Accessibility Statement

Teva code of conduct


Norway, Finland, Denmark: AJO-DK-NP-00128